Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206081 | 0.84 | ERN1 (0.38) | FFAR1MRGPRX4PPARD | |
| SCHEMBL3008775 | 0.78 | FFAR1 (0.62) | FFAR1PPARD | |
| SCHEMBL2690136 | 0.76 | FFAR1 (0.55) | FFAR1PPARD | |
| SCHEMBL205346 | 0.75 | TTR (0.46) | FFAR1PPARDFFAR4 | |
| SCHEMBL24983682 | 0.71 | ELANE (0.49) | MRGPRX4PTGER1 | |
| SCHEMBL15125764 | 0.70 | FFAR1 (0.54) | FFAR1FFAR4 | |
| SCHEMBL16532872 | 0.70 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL16239319 | 0.69 | CD274 (0.51) | FFAR1MRGPRX4 | |
| SCHEMBL15125788 | 0.69 | CD274 (0.51) | FFAR1MRGPRX4 | |
| SCHEMBL16347689 | 0.67 | RXRG (0.41) | FFAR1MRGPRX4FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2248812-B1 | FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8598226-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8088821-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| EP-2248812-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885MRGPRX4 47/4885PPARD 128/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885MRGPRX4 47/4885PPARD 128/4885 |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885MRGPRX4 47/4885PPARD 128/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | FFAR1 15/4885MRGPRX4 47/4885PPARD 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.